Treatment Strategies - Merits of Targeting LDL - C, Triglycerides, HDL - C, and Non - HDL - C, and Addressing Residual Risk


  • What risk factors contribute to a patient's total risk profile for cardiometabolic disease, including residual CAD risk?
  • How does targeting HDL - C vs HDL - P affect risk?
  • What are the merits of targeting (reducing) TG and how does the setting of high cholesterol contribute to risk associated with high TGs?
  • What are the benefits of lowering LDL - C, non - HDL - C, Apo B, and LDL - P? How low should LDL - C lowering go?
Download Slides (PDF)